‘Last resort’ COVID-19 treatment outperforms molnupiravir in trial
Infectious diseases expert Professor Robert Booy says there is enough evidence to prompt a review of sotrovimab’s role in Australia
A leading infectious diseases expert has urged health authorities to rethink their stance on the COVID-19 treatment sotrovimab, with new evidence suggesting it may outperform molnupiravir in preventing severe disease.
National treatment guidelines currently recommend the monoclonal antibody should only be used as a last resort because of the lack of clinical evidence backing its efficacy against the Omicron subvariants.
